What? Another Brentjens paper?

Reprogrammed is a biotechnology podcast exploring the development of cell therapies, with this season focusing on CAR T cells in cancer treatment. The Brentjens et al. (2013) study marked a pivotal moment in the clinical application of CAR T therapy, demonstrating for the first time that second-generation CD19 CAR T cells incorporating a CD28 co-stimulatory domain could induce molecular remission in adults with relapsed/refractory B-ALL. By bridging the gap between preclinical engineering and real-world application, this study laid the foundation for the eventual FDA approval of CD19-directed CAR T therapies for B-cell malignancies